Triplostoside A exhibits significant anti-inflammatory and immunomodulatory activities, making it a candidate for development in treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. It has demonstrated the ability to suppress pro-inflammatory cytokines, including TNF-α and IL-6, in cellular models. Additionally, Triplostoside A shows potential neuroprotective effects, with studies indicating its role in reducing oxidative stress and neuronal damage in vitro, suggesting possible application in neurodegenerative conditions like Alzheimer’s disease. Its natural origin and low cytotoxicity profile further support its use in pharmaceutical research focused on safe and effective therapeutic agents.